MedPath

KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer

Not Applicable
Completed
Conditions
Prostate Carcinoma
Adult Liver Carcinoma
Malignant Pancreatic Neoplasm
Interventions
Device: Cone-Beam Computed Tomography
Radiation: 3-Dimensional Ultrasound-Guided Radiation Therapy
Registration Number
NCT02337465
Lead Sponsor
Case Comprehensive Cancer Center
Brief Summary

This clinical trial studies if kilo-voltage cone beam computed tomography (KV-CBCT) and ultrasound imaging works in guiding radiation therapy in patients with prostate, liver, or pancreatic cancer. Computer systems, such as KV-CBCT and ultrasound imaging, allow doctors to create a 3-dimensional picture of the tumor may help in planning radiation therapy and may result in more tumor cells being killed.

Detailed Description

PRIMARY OBJECTIVES:

I. To investigate the feasibility of combining on-board cone beam computed tomography (CBCT) with ultrasound imaging to overcome the shortcomings of CBCT or ultrasound imaging alone for imaging guided radiotherapy delivery.

OUTLINE:

Patients undergo ultrasound imaging prior to and during radiation therapy. Patients also undergo kilo-voltage cone beam computed tomography prior to radiation therapy.

Update (2021/02/04): Removed secondary outcome "Incidence of Adverse Events Related to the Ultrasound Probe". Per PI: Study initially intended to involve a non-FDA approved probe for use with liver patients but removed this section.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • The patient must have either 1) cancer involving the liver by biopsy or radiographic criteria, or 2) prostate cancer by biopsy, with the intent of undergoing definitive dose radiation therapy to targets within the liver, or prostate. Patients with prostatectomy receiving post-operative radiotherapy are also eligible.
  • Karnofsky performance status (PS) ≥ 70
  • Subjects must have the ability to understand and the willingness to sign a written informational form
Exclusion Criteria
  • Patients with uncontrolled inter-current illness or psychiatric illness/social situations that would limit compliance with study requirements

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)Cone-Beam Computed TomographyPatients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)3-Dimensional Ultrasound-Guided Radiation TherapyPatients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
Primary Outcome Measures
NameTimeMethod
Number of Participants Able to Have the Ultrasound Probe Attached During the Entire Treatment CourseUp to 1 year

Proportion of participants able to have the ultrasound probe attached during the entire treatment course

Percentage of Ultrasound Images Which Are Clinically Adequate for Treatment Set-upUp to 1 year

Percentage of ultrasound images which are clinically adequate for treatment set-up in the judgment of the treating physician

Percent of Patients Whose Plan Quality Was Not Not Affected in the Presence of the Ultrasound ProbeUp to 1 year

Quality of plans for patients not affected in the presence of the ultrasound probe, defined as no more than a 2% decrease in tumor coverage, and also no more than a 2% increase in the dose to the most critical normal tissue for that tumor location

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

🇺🇸

Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath